Rapport Therapeutics, Inc.
RAPP
$47.42
$0.060.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 126.69% | 67.16% | -- | -- | -- |
| Gross Profit | -126.69% | 35.03% | -- | -- | -- |
| SG&A Expenses | 37.79% | 52.59% | 30.51% | 26.41% | 33.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 106.15% | 63.11% | 63.72% | 38.57% | 41.81% |
| Operating Income | -106.15% | 10.67% | -63.72% | -38.57% | -41.81% |
| Income Before Tax | -111.79% | 17.48% | -68.98% | -53.53% | -47.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -111.79% | 17.48% | -68.98% | -53.53% | -47.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -111.79% | 17.48% | -68.98% | -53.53% | -47.52% |
| EBIT | -106.15% | 10.67% | -63.72% | -38.57% | -41.81% |
| EBITDA | -107.20% | 10.71% | -64.41% | -38.79% | -42.02% |
| EPS Basic | -58.13% | 38.38% | -26.15% | -41.09% | 55.61% |
| Normalized Basic EPS | -58.12% | 38.39% | -26.14% | -41.05% | 55.60% |
| EPS Diluted | -58.13% | 38.38% | -26.15% | -41.09% | 55.61% |
| Normalized Diluted EPS | -58.12% | 38.39% | -26.14% | -41.05% | 55.60% |
| Average Basic Shares Outstanding | 33.94% | 33.94% | 33.96% | 8.82% | 232.30% |
| Average Diluted Shares Outstanding | 33.94% | 33.94% | 33.96% | 8.82% | 232.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |